Clinical trial readout dates for Roivant Sciences Ltd., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Market cap$27.0B
Cash & investments$4.21B~22 quarters at last loss rate
Recent 8-K filings2latest 2026-11-09
No trial records on file for this company.
Cash position
Roivant Sciences Ltd. reported $4.21B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $192M; at that rate the cash would last about 22 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
Recent SEC filings
8-KResults of Operations — earnings, may carry pipeline updates